Invesco Ltd. Has $191,000 Stock Holdings in Olema Pharmaceuticals, Inc. $OLMA

Key Points

• Invesco Ltd. increased its stake in Olema Pharmaceuticals by 208.9% during the 1st quarter, now holding a total of 50,810 shares worth approximately $191,000.
• Several large investors, including HSBC Holdings PLC and Bank of America Corp DE, have recently adjusted their positions in Olema Pharmaceuticals, contributing to a significant institutional ownership rate of 91.78%.
• Olema Pharmaceuticals reported a quarterly earnings loss of ($0.51) per share, which was below analysts' estimates, indicating challenges ahead as the company focuses on developing therapies for women's cancers.

Invesco Ltd. boosted its stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA - Free Report) by 208.9% in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 50,810 shares of the company's stock after buying an additional 34,362 shares during the period. Invesco Ltd. owned 0.07% of Olema Pharmaceuticals worth $191,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in OLMA. Hsbc Holdings PLC bought a new position in shares of Olema Pharmaceuticals during the 4th quarter valued at about $58,000. Northern Trust Corp lifted its stake in Olema Pharmaceuticals by 8.7% during the fourth quarter. Northern Trust Corp now owns 423,787 shares of the company's stock valued at $2,471,000 after buying an additional 34,053 shares in the last quarter. BNP Paribas Financial Markets purchased a new stake in Olema Pharmaceuticals during the fourth quarter valued at about $1,130,000. Bank of America Corp DE lifted its stake in Olema Pharmaceuticals by 110.6% during the fourth quarter. Bank of America Corp DE now owns 865,339 shares of the company's stock valued at $5,045,000 after buying an additional 454,400 shares in the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new stake in Olema Pharmaceuticals during the fourth quarter valued at about $152,000. Institutional investors own 91.78% of the company's stock.

Olema Pharmaceuticals Stock Down 2.9%

OLMA traded down $0.23 during midday trading on Friday, hitting $7.77. 1,345,330 shares of the company's stock traded hands, compared to its average volume of 938,510. The company has a market cap of $533.29 million, a PE ratio of -3.92 and a beta of 1.92. The stock's fifty day simple moving average is $5.47 and its 200-day simple moving average is $4.76. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.09 and a quick ratio of 11.09. Olema Pharmaceuticals, Inc. has a one year low of $2.86 and a one year high of $13.93.

Olema Pharmaceuticals (NASDAQ:OLMA - Get Free Report) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.08). As a group, equities analysts anticipate that Olema Pharmaceuticals, Inc. will post -2.33 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have commented on OLMA shares. Oppenheimer reaffirmed an "outperform" rating and set a $22.00 price objective on shares of Olema Pharmaceuticals in a research note on Wednesday, September 3rd. Citigroup upped their price objective on shares of Olema Pharmaceuticals from $20.00 to $21.00 and gave the company a "buy" rating in a research note on Tuesday, August 12th. JPMorgan Chase & Co. upped their price objective on shares of Olema Pharmaceuticals from $28.00 to $29.00 and gave the company an "overweight" rating in a research note on Thursday, August 14th. Finally, Zacks Research raised shares of Olema Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Tuesday. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $24.00.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.